Harmony Biosciences Holdings, Inc.

Harmony Biosciences reported Q1 2026 net product revenue of $215.4 million, a 17% increase year-over-year, and reaffirmed its full-year 2026 net revenue guidance of over $1 billion. Despite strong demand for WAKIX, net income decreased by 29% to $32.5 million, or $0.55 per diluted share, primarily due to $32.0 million in upfront payments for new license agreements. The company is advancing its pipeline, protecting WAKIX IP, and focusing on business development, including new COO and CFO appointments.

Harmony Biosciences reported Q1 2026 net product revenue of $215.39 million, a 16.6% increase year-over-year. However, net income decreased by 28.7% to $32.49 million, and diluted EPS fell to $0.55, primarily due to a 100.9% surge in research and development expenses. The company entered into new license agreements with Novitium Pharma and MSN Laboratories, incurring upfront fees for future product development.

Harmony Biosciences Holdings, Inc. announced a change in its Chief Financial Officer role, effective April 14, 2026. Sandip Kapadia stepped down to pursue other career opportunities and will receive severance benefits in accordance with his employment agreement. Glenn Reicin, aged 61, has been appointed as the new Chief Financial Officer. Mr. Reicin brings significant experience, having previously served as CFO at Eccogene, Inc. and as CFO and COO at Alladapt Immunotherapeutics, Inc.

Harmony Biosciences Holdings, Inc. announced a change in its Chief Financial Officer position. Sandip Kapadia stepped down as CFO, effective April 14, 2026, to pursue other career opportunities. Concurrently, Glenn Reicin was appointed as the new Chief Financial Officer, effective the same day. Mr. Reicin brings extensive experience, having previously served as CFO at Eccogene, Inc. and Alladapt Immunotherapeutics, Inc.